Key Insights

Highlights

Success Rate

77% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

4.9%

3 terminated out of 61 trials

Success Rate

76.9%

-9.6% vs benchmark

Late-Stage Pipeline

11%

7 trials in Phase 3/4

Results Transparency

40%

4 of 10 completed with results

Key Signals

4 with results77% success

Data Visualizations

Phase Distribution

44Total
Not Applicable (10)
Early P 1 (2)
P 1 (5)
P 2 (20)
P 3 (5)
P 4 (2)

Trial Status

Unknown29
Completed10
Recruiting8
Not Yet Recruiting8
Terminated3
Enrolling By Invitation2

Trial Success Rate

76.9%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (61)

Showing 20 of 20 trials
NCT07396480Phase 3Recruiting

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

NCT05149365Phase 3Completed

Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation

NCT06028828Phase 2RecruitingPrimary

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

NCT07324291Not Yet RecruitingPrimary

Perianal MBL-CRE Colonization and Infection in Allogeneic Hematopoietic Stem Cell Transplant Patients

NCT07181330Completed

Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantation

NCT07157670Not Yet Recruiting

Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

NCT07145359Not ApplicableNot Yet Recruiting

Virtual Reality Intervention for Symptom Management in Stem Cell Transplantation

NCT07094464Phase 1Active Not Recruiting

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

NCT07013370Recruiting

Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT06946654Not Yet Recruiting

Geriatric Assessment (GA) for Elderly Patients Undergoing Allo-HSCT

NCT06686108Phase 2Recruiting

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

NCT06802406Not ApplicableRecruitingPrimary

Nutrition OUtReach In Systems of Healthcare

NCT06912347Not ApplicableEnrolling By InvitationPrimary

Acupoint Application With Herbal Fumigation and Wash for Preventing Diarrhea-induced Perianal Infection in Allo-HSCT Patients

NCT03378102Early Phase 1RecruitingPrimary

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

NCT05674539Phase 3Enrolling By Invitation

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT06708130RecruitingPrimary

Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study

NCT06704542Not Yet RecruitingPrimary

Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation

NCT06673459Phase 3Not Yet Recruiting

BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients

NCT04995653Phase 1CompletedPrimary

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

NCT05692713Unknown

Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)

Scroll to load more

Research Network

Activity Timeline